Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.
Breaking News:
- GBM Launches the UAE’s First AI Lab Powered by Cisco Secure AI Factory with NVIDIA – Delivering Sovereign AI Infrastructure
- Cleaning Robot Adoption Accelerates Globally as Russia Targets 23,000 Units by 2030
- Cloudera and stc group Partner to Accelerate Digital Transformation Across the Middle East
- CLUB 15: THE 15,000 SQM SPORTS CITY WITHIN THE CITY ARRIVING IN DUBAI
- IHG Hotels at Dubai Festival City Marks Breast Cancer Awareness Month with Pink October Initiatives
- Hybrid Vehicles Bring Greater Everyday Value to UAE Motorists
- THE TOUCHLAND MIST FOR EVERY WORKOUT PERSONALITY
- FITNESS CHAMPION AND MEDIA PERSONALITY MAYA NASSAR MAALOUF MARKS 40TH BIRTHDAY WITH INSPIRATIONAL “VOICES OF HOPE” EVENT IN BEIRUT
Wednesday, October 7
